FibroBiologics (FBLG) Enterprise Value (2024 - 2026)

FibroBiologics (FBLG) has reported Enterprise Value for 3 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 83.67% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (down 83.67% YoY), and the FY2025 full-year result was $10.1 million, down 83.62% from the prior year.
• Enterprise Value retreated to $2.8 million in Q2 2026 per FBLG's latest filing, from $3.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at $345.5 million in Q1 2024 and bottomed at $2.8 million in Q2 2026.
• Historically, Enterprise Value has averaged $75.8 million across 3 years, with a median of $24.5 million in 2025.
• The widest YoY moves for Enterprise Value: up 76.63% in 2025, down 92.54% in 2025.
• Over 3 years, Enterprise Value stood at $61.5 million in 2024, then slumped by 83.62% to $10.1 million in 2025, then sank by 72.09% to $2.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $2.8 million, $3.5 million, and $10.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.